Search Results - "Sebaldt, R J"

Age and drug therapy are key prognostic factors for first clinical fracture in patients with primary osteoporosis by GAJIC-VELJANOSKI, O, SEBALDT, R. J, DAVIS, A. M, TRITCHLER, D, TOMLINSON, G, PETRIE, A, ADACHI, J. D, CHEUNG, A. M

“…We evaluated the characteristics of 1,142 women and men who attended Canadian osteoporosis clinics and had T-score < or = -2.0 and no prior fractures to…”
Get full text

Effectiveness of alendronate and etidronate in the treatment of osteoporosis in men : a prospective observational study by OLSZYNSKI, W. P, DAVISON, K. S, PETRIE, A, GOLDSMITH, C. H, ADACHI, J. D, IOANNIDIS, G, BROWN, J. P, HANLEY, D. A, JOSSE, R. G, MURRAY, T. M, PAPAIOANNOU, A, SEBALDT, R. J, TENENHOUSE, A. M

“…The prevalence of osteoporosis in men is higher than previously assumed; consequently, numerous therapies are being investigated to treat these patients. The…”
Get full text

Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup by Adachi, J D, Bensen, W G, Bianchi, F, Cividino, A, Pillersdorf, S, Sebaldt, R J, Tugwell, P, Gordon, M, Steele, M, Webber, C, Goldsmith, C H

“…To determine the efficacy and safety of vitamin D 50,000 units/week and calcium 1,000 mg/day in the prevention of corticosteroid induced osteoporosis. A…”
Get more information

Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss by Adachi, J, Cranney, A, Goldsmith, C H, Bensen, W G, Bianchi, F, Cividino, A, Craig, G L, Kaminska, E, Sebaldt, R J, Papaioannou, A

“…To assess the potential efficacy of intermittent cyclic therapy (ICT) with etidronate in the treatment of patients with corticosteroid induced osteoporosis…”
Get more information

Inhibition of Eicosanoid Biosynthesis by Glucocorticoids in Humans by Sebaldt, Rolf J., Sheller, James R., Oates, John A., Roberts, L. Jackson, FitzGerald, Garret A.

“…Therapeutic doses of glucocorticoids are thought to inhibit prostaglandin and leukotriene formation in humans. Several studies in animals, however, have failed…”
Get full text

Predicting subsequent bone density response to intermittent cyclical therapy with etidronate from initial density response in patients with osteoporosis by CRILLY, R. G, SEBALDT, R. J, HODSMAN, A. B, ADACHI, J. D, BROWN, J. P, GOLDSMITH, C. H, HANLEY, D. A, OLSZYNSKI, W. O, STE-MARIE, L.-G, STEPHENSON, G. F

“…We investigated whether an increase in lumbar spine bone mineral density (LS BMD) at 6 months or at 12 months could predict the response to intermittent…”
Get full text

The association between iliocostal distance and the number of vertebral and non-vertebral fractures in women and men registered in the Canadian Database For Osteoporosis and Osteopenia (CANDOO) by Olszynski, W P, Ioannidis, G, Sebaldt, R J, Hanley, D A, Petrie, A, Brown, J P, Josse, R G, Murray, T M, Goldsmith, C H, Stephenson, G F, Papaioannou, A, Adachi, J D

“…The identification of new methods of evaluating patients with osteoporotic fracture should focus on their usefulness in clinical situations such that they are…”
Get full text

Formation of second messenger diradylglycerol in murine peritoneal macrophages is altered after in vivo (n-3) polyunsaturated fatty acid supplementation by Marignani, P A, Sebaldt, R J

“…The consequences of macrophage membrane incorporation of (n-3) polyunsaturated fatty acids (PUFA) on diradylglycerol (DG) formation and phospholipase-mediated…”
Get more information

36 month intermittent cyclical etidronate treatment in patients with established corticosteroid induced osteoporosis by Sebaldt, R J, Ioannidis, G, Adachi, J D, Bensen, W G, Bianchi, F, Cividino, A, Gordon, M, Kaminska, E, Scocchia, T, Petrie, A, Stephenson, G F, Goldsmith, C H

“…To determine the longterm safety and efficacy of etidronate therapy in patients in whom corticosteroid induced bone loss has already occurred. We performed a…”
Get more information

Evaluation of a chronic disease management system for the treatment and management of diabetes in primary health care practices in Ontario: an observational study by O'Reilly, D J, Bowen, J M, Sebaldt, R J, Petrie, A, Hopkins, R B, Assasi, N, MacDougald, C, Nunes, E, Goeree, R

“…Computerized chronic disease management systems (CDMSs), when aligned with clinical practice guidelines, have the potential to effectively impact diabetes…”
Get full text

Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database by PAPAIOANNOU, Alexandra, IOANNIDIS, George, HANLEY, David A, JOSSE, Robert, MURRAY, Timothy M, PETRIE, Annie, GOLDSMITH, Charlie H, ADACHI, Jonathan D, SEBALDT, Rolf J, FERKO, Nicole, PUGLIA, Mark, BROWN, Jacques, TENENHOUSE, Alan, OLSZYNSKI, Wojciech P, BOULOS, Pauline

“…Therapies for osteoporosis must be taken for at least 1 year to be effective. The purpose of this study was to determine the difference in adherence to…”
Get full text

Quantification of contributions of phospholipid precursors to diradylglycerols in stimulated mononuclear phagocytes by SEBALDT, R. J, ADAMS, D. O, UHING, R. J

“…Phosphatidylcholine (PC) hydrolysis has been shown to occur in hormone-stimulated cells and represents a potential metabolic source, in addition to…”
Get full text

Analysis of Environmental Factors in Familial Versus Sporadic Paget's Disease of Bone—The New England Registry for Paget's Disease of Bone by Seton, Margaret, Choi, Hyon K, Hansen, Marc F, Sebaldt, Rolf J, Cooper, Cyrus

“…A registry for Paget's Disease (PD) was created to study the environmental and familial features of this disorder. This study examines the first 202 people…”
Get full text

The formation of diradylglycerol molecular species in murine peritoneal macrophages varies dose-dependently with dietary purified eicosapentaenoic and docosahexaenoic ethyl esters by Marignani, P A, Sebaldt, R J

“…Substantial effects of dietary fish oil-derived fatty acid ethyl esters on the metabolism of diradylglycerol (DG) have recently been described. We undertook to…”
Get more information

Information technology and the future of medical education by Sebaldt, R J

Get more information

Fluoride therapy in prevention of rheumatoid arthritis induced bone loss by Adachi, J D, Bell, M J, Bensen, W G, Bianchi, F, Cividino, A, Sebaldt, R J, Gordon, M, Ioannidis, G, Goldsmith, C

“…To determine the efficacy of sodium fluoride (40 mg/day) in preventing rheumatoid arthritis (RA) induced bone loss, which may lead to osteoporosis. We…”
Get more information

Pulse steroid therapy and the search for improved drug therapy of rheumatoid arthritis by Sebaldt, R J

Get more information

Intermittent cyclic therapy with etidronate prevents corticosteroid-induced bone loss: two years of follow-up by Sebaldt, R J, Adachi, J D, Bensen, W G, Bianchi, F, Cividano, A, Craig, G L, Cranney, A, Kaminska, E, Gordon, M, Steele, M, Goldsmith, C

“…The purpose of this study was to evaluate the efficacy of intermittent cyclic therapy (ICT) with etidronate in preventing the loss of lumbar vertebral bone…”
Get more information

A shorter plasma half life does not predict less drug accumulation by Sebaldt, R J

Get more information

IFN-gamma potentiates the accumulation of diacylglycerol in murine macrophages by Sebaldt, RJ, Prpic, V, Hollenbach, PW, Adams, DO, Uhing, RJ

“…Activation of mononuclear phagocytes for a variety of functional responses is potentiated by prior exposure to IFN-gamma. Inasmuch as protein kinase C has been…”
Get full text